The Drugs.com Monthly Update Podcast

Drugs.com•www.drugs.com

The "Monthly Update" Podcast from Drugs.com delivers monthly roundups of new drug approvals, updated indications, safety alerts, and the latest healthcare news.

Last refreshed: April 17th, 2026 at 1:24 AM ⓘ

Follow this podcast in the Metacast mobile app to refresh it and see new episodes.

Follow on

Apple Podcasts

Spotify

RSS

Podcasts are better in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

Drugs.com - Monthly Update March 2026

In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes. Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials. Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment c...

Apr 02, 2026•5 min•Ep. 10

Drugs.com - Monthly Update February 2026

In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC. Zepbound KwikPen (tirzepatide): A new mu...

Mar 02, 2026•5 min•Ep. 9

Drugs.com - Monthly Update January 2026

In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin. Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma. Yuve...

Feb 02, 2026•6 min•Ep. 8

Drugs.com - Monthly Update December 2025

This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up. Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials. Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy ...

Jan 01, 2026•5 min•Ep. 7

Drugs.com - Monthly Update November 2025

In this episode, we explore key FDA approvals from November 2025, including treatments like Keytruda Qlex for bladder cancer, Epkinly for follicular lymphoma, and the long-acting Eylea HD for macular edema. Discover what these developments mean for patients and professionals alike. Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, demonstrating a 60% reduction in ...

Dec 01, 2025•4 min•Ep. 6

Drugs.com - Monthly Update October 2025

This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes. Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes. Zoryve (roflumilast): A breakthrough stero...

Nov 01, 2025•5 min•Ep. 5

Drugs.com - Monthly Update September 2025

Discover the latest in pharmaceutical advancements with our September 2025 roundup. We're covering newly approved treatments like Rhapsido for chronic spontaneous urticaria, Palsonify for acromegaly, and Inluriyo for ESR1-mutated breast cancer. Learn about groundbreaking therapies, their impacts on patient care, and what these mean for healthcare professionals and patients alike. Rhapsido (remibrutinib) for the management of difficult chronic spontaneous urticaria in adults still experiencing sy...

Oct 01, 2025•5 min•Ep. 4

Drugs.com - Monthly Update August 2025

August 2025 brought significant advances in therapies for conditions ranging from metabolic liver disease to pediatric migraine prevention and beyond. Tune in as we delve into key FDA approvals like Novo Nordisk's Wegovy for MASH, Tonmya for fibromyalgia, and Ajovy's pediatric migraine approval, and explore their implications in clinical practice. Wegovy (semaglutide) for metabolic liver disease: Now indicated for metabolic dysfunction-associated steatohepatitis (MASH) in adults, offering a new ...

Sep 01, 2025•5 min•Ep. 3

Drugs.com - Monthly Update July 2025

This month we explore groundbreaking FDA approvals including Ekterly for hereditary angioedema, Anzupgo for chronic hand eczema, and the new dosing regimen of Kisunla for Alzheimer’s. We’ll discuss the mechanisms, patient impacts, and data that drive these advancements. Ekterly (sebetralstat), approved as an oral on-demand treatment for hereditary angioedema (HAE) attacks in patients 12 years and older, providing symptom relief in just 1.6 hours compared to 6.7 hours with placebo. Anzupgo (delgo...

Aug 02, 2025•4 min•Ep. 2

Drugs.com - Monthly Update June 2025

This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas. Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65. Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old. Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable H...

Jul 02, 2025•5 min•Ep. 1

Hosted on Transistor

For the best experience, listen in Metacast app for iOS or Android